secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0000059478-24-000116
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q1 revenue up 26% to $8.77B; raises full-year guidance by $2B
-------------------------------------------------------------------

- Q1 reported EPS $2.48 (up 66% YoY); non-GAAP EPS $2.58 (up 59% YoY), including $0.10 acquired IPR&D charges.
- Revenue $8.77B, driven by Mounjaro, Zepbound, Verzenio, Jardiance; raised FY2024 revenue guidance by $2.0B.
- Raises FY2024 reported EPS guidance to $13.05-$13.55 and non-GAAP EPS to $13.50-$14.00.
- Pipeline progress: positive Phase 3 tirzepatide for OSA, mirikizumab submission for Crohn's, lebrikizumab resubmission.
- Agreement to acquire injectable medicine manufacturing facility from Nexus Pharmaceuticals; broke ground on $2.5B German site.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947824000116/0000059478-24-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947824000116/lly-20240430.htm
  HTML page:      https://secwatch.observer/filing/0000059478-24-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer